alpha-synuclein targeted antibody / Eli Lilly, SciNeuro Pharma - LARVOL DELTA

SciNeuro Pharmaceuticals Announces Exclusive Licensing Agreement with Eli Lilly & Company (Businesswire) - "Alpha-synuclein Directed Therapies May Have Utility in Parkinson’s Disease and Related Neurological Disorders, Which Represent a Significant Unmet Medical Need...SciNeuro Pharmaceuticals...has entered into an exclusive license agreement with Eli Lilly and Company (NYSE: LLY) for the development and commercialization of alpha-synuclein targeted antibody therapies in Greater China..."

Licensing / partnership • CNS Disorders • Parkinson's Disease